|   | (Mark One)                                                    |                                                               |   |
|--------|---------------------------------------------------------------|--------------------------------------------------------------------|--------|
|   |          X       | Quarterly Report Pursuant to Section 13 or 15(d)                   |   |
|   |                                                          | of the Securities Exchange Act of 1934                             |   |
|   |                                                          |                                                               |   |
|   |                                                          | For the quarterly period ended:   February 28, 2010 |   |
|   |                                                          | OR                                                                 |   |
|   |           _ | Transition Report Pursuant to Section 13 or 15(d)                  |   |
|   |                                                          | of the Securities Exchange Act of 1934                             |   |

| Georgia                         | 22-2408354          |
|---------------------------------|---------------------|
| (State or other jurisdiction of | (I.R.S. Employer    |
| incorporation or organization)  | Identification No.) |

| Large accelerated filer X                   | Accelerated filer         |
|---------------------------------------------|---------------------------|
|                                        |                      |
| Non-accelerated filer                       | Smaller reporting company |
| (do not check if smaller reporting company) |                      |

----

| PART I.    FINANCIAL INFORMATION |
|-------------------------------------------------|
|                                            |   |   |
| Item 1.                                         | Financial Statements |   |
|                                            |   |   |
|                                            | Condensed Consolidated Balance Sheets as of February 28, 2010 (unaudited) and May 31, 2009 |   |
|                                            |   |   |
|                                            | Condensed Consolidated Statements of Income for the three and nine months ended February 28, 2010 (unaudited) and February 28, 2009 (unaudited) |   |
|                                            |   |   |
|                                            | Condensed Consolidated Statement of Shareholders’ Equity and Comprehensive Income |   |
|                                            | for the period June 1, 2009 through February 28, 2010 (unaudited) |   |
|                                            |   |   |
|                                            | Condensed Consolidated Statements of Cash Flows for the nine months ended February 28, 2010 (unaudited) and February 28, 2009 (unaudited) |   |
|                                            |   |   |
|                                            | Notes to Condensed Consolidated Financial Statements (unaudited) |   |
|                                            |   |   |
| Item 2.                                         | Management's Discussion and Analysis of Financial Condition and Results of Operations |   |
|                                            |   |   |
| Item 3.                                         | Quantitative and Qualitative Disclosures about Market Risk |   |
|                                            |   |   |
| Item 4.                                         | Controls and Procedures |   |
|                                            |   |   |
| PART II.   OTHER INFORMATION          |
|                                            |   |   |
| Item 1.                                         | Legal Proceedings |   |
|                                            |   |   |
| Item 1A.                                        | Risk Factors |   |
|                                            |   |   |
| Item 2.                                         | Unregistered Sales of Equity Securities and Use of Proceeds |   |
|                                            |   |   |
| Item 6.                                         | Exhibits |   |
|                                            |   |   |
|                                            | SIGNATURES |   |

----

| ITEM 1. Financial Statements              |
|-------------------------------------------|
| IMMUCOR, INC. AND SUBSIDIARIES            |
| CONDENSED CONSOLIDATED BALANCE SHEETS     |
| (Amounts in thousands, except share data) |

|                                                                                              |   |              |    |   |         |   |
|---------------------------------------------------------------------------------------------------|--------|-------------------|---------|--------|--------------|--------|
|                                                                                              |   | February 28, 2010 |    |   | May 31, 2009 |   |
| ASSETS                                                                                            |   | (Unaudited)       |    |   |         |   |
|                                                                                              |   |              |    |   |         |   |
| CURRENT ASSETS:                                                                                   |   |              |    |   |         |   |
| Cash and cash equivalents                                                                         |   | $                 | 175,622 |   |         | $      | 136,461 |   |
| Trade accounts receivable, net of allowance for doubtful accounts of $2,238 at                    |   |              |    |   |         |   |   |   |
| February 28, 2010 and $2,179 at May 31, 2009                                                      |   |              | 61,670  |   |         |   | 57,017 |   |
| Inventories                                                                                       |   |              | 37,922  |   |         |   | 38,256 |   |
| Deferred income tax assets, current portion                                                       |   |              | 7,751   |   |         |   | 7,979 |   |
| Prepaid expenses and other current assets                                                         |   |              | 4,870   |   |         |   | 5,137 |   |
| Total current assets                                                                              |   |              | 287,835 |   |         |   | 244,850 |   |
|                                                                                              |   |              |    |   |         |   |   |   |
| PROPERTY AND EQUIPMENT, Net                                                                       |   |              | 48,823  |   |         |   | 43,461 |   |
| GOODWILL                                                                                          |   |              | 95,008  |   |         |   | 97,255 |   |
| INTANGIBLE ASSETS, Net                                                                            |   |              | 58,482  |   |         |   | 61,355 |   |
| DEFERRED INCOME TAX ASSETS                                                                        |   |              | 4,164   |   |         |   | 3,638 |   |
| OTHER ASSETS                                                                                      |   |              | 571     |   |         |   | 781 |   |
| Total assets                                                                                      |   | $                 | 494,883 |   |         | $      | 451,340 |   |
|                                                                                              |   |              |    |   |         |   |   |   |
| LIABILITIES AND SHAREHOLDERS' EQUITY                                                              |   |              |    |   |         |   |   |   |
|                                                                                              |   |              |    |   |         |   |   |   |
| CURRENT LIABILITIES:                                                                              |   |              |    |   |         |   |   |   |
| Accounts payable                                                                                  |   | $                 | 7,852   |   |         | $      | 9,344 |   |
| Accrued expenses and other current liabilities                                                    |   |              | 14,173  |   |         |   | 20,253 |   |
| Income taxes payable                                                                              |   |              | 11,835  |   |         |   | 11,469 |   |
| Deferred revenue, current portion                                                                 |   |              | 10,144  |   |         |   | 11,222 |   |
| Total current liabilities                                                                         |   |              | 44,004  |   |         |   | 52,288 |   |
|                                                                                              |   |              |    |   |         |   |   |   |
| DEFERRED REVENUE                                                                                  |   |              | 8,607   |   |         |   | 10,871 |   |
| DEFERRED INCOME TAX LIABILITIES                                                                   |   |              | 1,117   |   |         |   | 1,272 |   |
| OTHER LONG-TERM LIABILITIES                                                                       |   |              | 2,185   |   |         |   | 2,331 |   |
| Total liabilities                                                                                 |   |              | 55,913  |   |         |   | 66,762 |   |
| COMMITMENTS AND CONTINGENCIES (Note 9)                                                            |   |              | -       |   |         |   | - |   |
| SHAREHOLDERS' EQUITY:                                                                             |   |              |    |   |         |   |   |   |
| Common stock, $0.10 par value; authorized 120,000,000 shares, issued and outstanding              |   |              |    |   |         |   |   |   |
| 69,881,314 and 70,456,522 shares at February 28, 2010 and May 31, 2009, respectively              |   |              | 6,988   |   |         |   | 7,046 |   |
| Additional paid-in capital                                                                        |   |              | 34,985  |   |         |   | 42,012 |   |
| Retained earnings                                                                                 |   |              | 388,338 |   |         |   | 327,242 |   |
| Accumulated other comprehensive income                                                            |   |              | 8,659   |   |         |   | 8,278 |   |
| Total shareholders' equity                                                                        |   |              | 438,970 |   |         |   | 384,578 |   |
| Total liabilities and shareholders' equity                                                        |   | $                 | 494,883 |   |         | $      | 451,340 |   |
|                                                                                              |   |              |    |   |         |   |   |   |
| The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. |   |              |    |   |         |

----

| IMMUCOR, INC. AND SUBSIDIARIES                |
|-----------------------------------------------|
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME   |
| (Amounts in thousands, except per share data) |
| (Unaudited)                                   |

|                                                                                                             |   | Three Months Ended |   |   | Nine Months Ended |   |
|------------------------------------------------------------------------------------------------------------------|--------|--------------------|--------|--------|-------------------|--------|
|                                                                                                             |   | February 28,       |   |   | February 28,      |   |   | February 28, |   |   | February 28, |   |
|                                                                                                             |   | 2010               |   |   | 2009 (1)          |   |   | 2010 |   |   | 2009 (1) |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |
| NET SALES                                                                                                        |   | $                  | 80,499 |   |              | $      | 75,309 |   |   | $ | 246,141 |   |   | $ | 221,506 |   |
| COST OF SALES(exclusive of amortization shown separately below)                                                  |   |               | 24,785 |   |              |   | 21,520 |   |   |   | 72,598 |   |   |   | 60,734 |   |
| GROSS PROFIT                                                                                                     |   |               | 55,714 |   |              |   | 53,789 |   |   |   | 173,543 |   |   |   | 160,772 |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES:                                                                                              |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Research and development                                                                                         |   |               | 3,409  |   |              |   | 2,777 |   |   |   | 11,130 |   |   |   | 7,553 |   |
| Selling and marketing                                                                                            |   |               | 8,388  |   |              |   | 8,894 |   |   |   | 27,617 |   |   |   | 28,626 |   |
| Distribution                                                                                                     |   |               | 3,579  |   |              |   | 3,309 |   |   |   | 10,805 |   |   |   | 10,326 |   |
| General and administrative                                                                                       |   |               | 8,399  |   |              |   | 8,440 |   |   |   | 25,907 |   |   |   | 23,816 |   |
| Amortization expense                                                                                             |   |               | 1,065  |   |              |   | 1,071 |   |   |   | 3,205 |   |   |   | 2,667 |   |
| Total operating expenses                                                                                         |   |               | 24,840 |   |              |   | 24,491 |   |   |   | 78,664 |   |   |   | 72,988 |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| INCOME FROM OPERATIONS                                                                                           |   |               | 30,874 |   |              |   | 29,298 |   |   |   | 94,879 |   |   |   | 87,784 |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| NON-OPERATING INCOME (EXPENSE):                                                                                  |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Interest income                                                                                                  |   |               | 56     |   |              |   | 427 |   |   |   | 340 |   |   |   | 1,808 |   |
| Interest expense                                                                                                 |   |               | (16    | )      |              |   | (42 | ) |   |   | (29 | ) |   |   | (245 | ) |
| Other, net                                                                                                       |   |               | (521   | )      |              |   | (312 | ) |   |   | (539 | ) |   |   | (1,964 | ) |
| Total non-operating income (expense)                                                                             |   |               | (481   | )      |              |   | 73 |   |   |   | (228 | ) |   |   | (401 | ) |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| INCOME BEFORE INCOME TAXES                                                                                       |   |               | 30,393 |   |              |   | 29,371 |   |   |   | 94,651 |   |   |   | 87,383 |   |
| PROVISION FOR INCOME TAXES                                                                                       |   |               | 10,332 |   |              |   | 9,914 |   |   |   | 33,555 |   |   |   | 30,632 |   |
| NET INCOME                                                                                                       |   | $                  | 20,061 |   |              | $      | 19,457 |   |   | $ | 61,096 |   |   | $ | 56,751 |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Earnings per share:                                                                                              |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Per common share - basic                                                                                         |   | $                  | 0.29   |   |              | $      | 0.28 |   |   | $ | 0.87 |   |   | $ | 0.81 |   |
| Per common share - diluted                                                                                       |   | $                  | 0.28   |   |              | $      | 0.27 |   |   | $ | 0.86 |   |   | $ | 0.80 |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                             |   |               |   |   |              |   |   |   |   |   |   |   |   |   |   |   |
| (1) Certain prior year operating expenses have been reclassified to conform with current year presentation. |   |               |   |   |              |
| The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.                |   |               |   |   |              |   |   |   |   |

----

| IMMUCOR, INC. AND SUBSIDIARIES                                                          |
|-----------------------------------------------------------------------------------------|
| CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY AND COMPREHENSIVE INCOME |
| (Unaudited, amounts in thousands)                                                       |

|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |
|---------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|--------|---------|--------|--------|------------|--------|--------|---------------|--------|--------|---------------------|---------|--------|--------|--------|
|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   | Accumulated         |    |   |   |   |
|                                                                                                                                  |   |         |   |   |    |   |   | Additional |   |   |          |   |   | Other               |    |   | Total  |   |
|                                                                                                                                  |   | Common Stock |   |   | Paid-In |   |   | Retained   |   |   | Comprehensive |   |   | Shareholders’ |    |
|                                                                                                                                  |   | Shares       |   |   | Amount  |   |   | Capital    |   |   | Earnings      |   |   | Income*             |    |   | Equity |   |
|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |
| BALANCE, MAY 31, 2009                                                                                                                 |   |         | 70,456 |   |    | $      | 7,046  |       |   | $      | 42,012        |   |   | $                   | 327,242 |   |   | $      | 8,278 |   |   | $ | 384,578 |   |
| Shares issued under employee stock plan                                                                                               |   |         | 84     |   |    |   | 8      |       |   |   | 261           |   |   |                | -       |   |   |   | - |   |   |   | 269 |   |
| Share-based compensation expense                                                                                                      |   |         | -      |   |    |   | -      |       |   |   | 4,164         |   |   |                | -       |   |   |   | - |   |   |   | 4,164 |   |
| Stock repurchases and retirements                                                                                                     |   |         | (659   | )      |    |   | (66    | )          |   |   | (11,661       | )      |   |                | -       |   |   |   | - |   |   |   | (11,727 | ) |
| Tax benefits related to share-based compensation                                                                                      |   |         | -      |   |    |   | -      |       |   |   | 209           |   |   |                | -       |   |   |   | - |   |   |   | 209 |   |
| Comprehensive income:                                                                                                                 |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustments                                                                                              |   |         | -      |   |    |   | -      |       |   |   | -             |   |   |                | -       |   |   |   | 381 |   |   |   | 381 |   |
| Net income                                                                                                                            |   |         | -      |   |    |   | -      |       |   |   | -             |   |   |                | 61,096  |   |   |   | - |   |   |   | 61,096 |   |
| Total comprehensive income                                                                                                            |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |   |   |   |   | 61,477 |   |
|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |   |   |   |   |   |   |
| BALANCE, FEBRUARY 28, 2010                                                                                                            |   |         | 69,881 |   |    | $      | 6,988  |       |   | $      | 34,985        |   |   | $                   | 388,338 |   |   | $      | 8,659 |   |   | $ | 438,970 |   |
|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |   |   |   |   |   |   |
| *Accumulated Other Comprehensive Income balance primarily consists of foreign currency translation adjustments and has no tax effect. |   |
|                                                                                                                                  |   |         |   |   |    |   |   |       |   |   |          |   |   |                |    |   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.                                     |   |         |   |   |    |

----

| IMMUCOR, INC. AND SUBSIDIARIES                  |
|-------------------------------------------------|
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
| (Unaudited, amounts in thousands)               |

|                                                                                              |   | Nine Months Ended |    |
|---------------------------------------------------------------------------------------------------|--------|-------------------|---------|
|                                                                                              |   | February 28,      |    |   | February 28, |   |
|                                                                                              |   | 2010              |    |   | 2009 |   |
| OPERATING ACTIVITIES:                                                                             |   |              |    |   |   |   |
| Net income                                                                                        |   | $                 | 61,096  |   |   | $ | 56,751 |   |
| Adjustments to reconcile net income to net cash provided by operating activities:                 |   |              |    |   |   |   |   |   |
| Depreciation and amortization                                                                     |   |              | 12,233  |   |   |   | 9,582 |   |
| Loss on retirement of fixed assets                                                                |   |              | 429     |   |   |   | 230 |   |
| Provision for doubtful accounts                                                                   |   |              | 306     |   |   |   | 905 |   |
| Share-based compensation expense                                                                  |   |              | 4,164   |   |   |   | 3,749 |   |
| Deferred income taxes                                                                             |   |              | (2,376  | ) |   |   | 1,453 |   |
| Excess tax benefit from share-based compensation                                                  |   |              | (209    | ) |   |   | (4,347 | ) |
| Changes in operating assets and liabilities, net of effects from acquired companies:              |   |              |    |   |   |   |   |   |
| Accounts receivable, trade                                                                        |   |              | (5,764  | ) |   |   | (8,689 | ) |
| Income taxes                                                                                      |   |              | 5,662   |   |   |   | 6,706 |   |
| Inventories                                                                                       |   |              | (9,423  | ) |   |   | (3,374 | ) |
| Other assets                                                                                      |   |              | 182     |   |   |   | (4,730 | ) |
| Accounts payable                                                                                  |   |              | (1,436  | ) |   |   | 1,338 |   |
| Deferred revenue                                                                                  |   |              | (3,349  | ) |   |   | (673 | ) |
| Accrued expenses and other liabilities                                                            |   |              | (5,992  | ) |   |   | (4,868 | ) |
| Cash provided by operating activities                                                             |   |              | 55,523  |   |   |   | 54,033 |   |
|                                                                                              |   |              |    |   |   |   |   |   |
| INVESTING ACTIVITIES:                                                                             |   |              |    |   |   |   |   |   |
| Purchases of property and equipment                                                               |   |              | (5,679  | ) |   |   | (6,088 | ) |
| Acquisition of businesses, net of cash acquired                                                   |   |              | -       |   |   |   | (108,659 | ) |
| Cash used in investing activities                                                                 |   |              | (5,679  | ) |   |   | (114,747 | ) |
|                                                                                              |   |              |    |   |   |   |   |   |
| FINANCING ACTIVITIES:                                                                             |   |              |    |   |   |   |   |   |
| Repayments of long-term debt and liabilities                                                      |   |              | -       |   |   |   | (213 | ) |
| Repurchase of common stock                                                                        |   |              | (11,727 | ) |   |   | (5,644 | ) |
| Proceeds from exercise of stock options                                                           |   |              | 269     |   |   |   | 3,107 |   |
| Excess tax benefit from share-based compensation                                                  |   |              | 209     |   |   |   | 4,347 |   |
| Cash provided by (used in) financing activities                                                   |   |              | (11,249 | ) |   |   | 1,597 |   |
|                                                                                              |   |              |    |   |   |   |   |   |
| EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS                                             |   |              | 566     |   |   |   | (2,514 | ) |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                                  |   |              | 39,161  |   |   |   | (61,631 | ) |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                                  |   |              | 136,461 |   |   |   | 175,056 |   |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                        |   | $                 | 175,622 |   |   | $ | 113,425 |   |
|                                                                                              |   |              |    |   |   |   |   |   |
| SUPPLEMENTAL INFORMATION:                                                                         |   |              |    |   |   |   |   |   |
| Tax paid                                                                                          |   | $                 | 30,178  |   |   | $ | 22,481 |   |
| Interest paid                                                                                     |   |              | -       |   |   |   | 37 |   |
| NON-CASH INVESTING AND FINANCING ACTIVITIES:                                                      |   |              |    |   |   |   |   |   |
| Shares surrendered for amounts due on stock options exercised                                     |   | $                 | -       |   |   | $ | 516 |   |
| Movement from inventory to property and equipment of instruments placed on rental agreements      |   |              | 9,444   |   |   |   | 5,134 |   |
|                                                                                              |   |              |    |   |   |   |   |   |
| The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. |   |

----

| 1. | NATURE OF BUSINESS AND BASIS OF PRESENTATION |
|----|----------------------------------------------|

| 2. | INVENTORIES |
|----|-------------|

|                       |   | February 28, 2010 |   |   | May 31, 2009 |   |
|----------------------------|--------|-------------------|--------|--------|--------------|--------|
|                       |   | (in thousands)    |   |
|                       |   |              |   |   |         |   |
| Raw materials and supplies |   | $                 | 8,591  |   |         | $      | 8,506 |   |
| Work in process            |   |              | 3,715  |   |         |   | 3,486 |   |
| Finished goods             |   |              | 25,616 |   |         |   | 26,264 |   |
|                       |   | $                 | 37,922 |   |         | $      | 38,256 |   |

| 3. | SHAREHOLDERS’ EQUITY |
|----|----------------------------|

----

| 4. | STOCK REPURCHASE PROGRAM |
|----|--------------------------|

| 5. | SHARE-BASED COMPENSATION |
|----|--------------------------|

|                        |   | Three Months Ended |   | Nine Months Ended |
|-----------------------------|--------|--------------------|--------|-------------------|
|                        |   | February 28,       |   | February 28,      |   | February 28, |   | February 28, |
|                        |   | 2010               |   | 2009              |   | 2010 |   | 2009 |
| Risk-free interest rate (1) |   | 2.07%              |   | 1.80%             |   | 2.15% |   | 3.19% |
| Expected volatility (2)     |   | 44.70%             |   | 42.80%            |   | 45.52% |   | 42.23% |
| Expected life (years) (3)   |   | 4.25               |   | 4.25              |   | 4.25 |   | 4.25 |
| Expected dividend yield (4) |   |  -            |   |  -           |   |  - |   |  - |

|   | 1.  | Based on the U.S. Treasury yield curve in effect at the time of grant. |
|--------|----------|------------------------------------------------------------------------|

|   | 2. | Expected stock price volatility is based on the average historical volatility of the      Company’s shares during the period corresponding to the expected life of the options. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Represents the period of time options are expected to remain outstanding.  As the Company has so far only awarded “plain vanilla options” as described by Accounting Standards Codification (“ASC”) 718-10-S99, “Compensation – Stock Compensation: Overall: SEC Materials”, the Company used the “simplified method” for determining the expected life of the options granted. The “simplified method” calculates expected term as the sum of the vesting term and the original contractual term divided by two. The Company will continue to use the “simplified method” until such time that it has sufficient historical data for options with six-year contractual terms to estimate the expected term of these share-based awards. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | The Company has not paid dividends on its common stock and does not expect to pay dividends on its common stock in the near future. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------|

----

|                             |   | Number of Shares |      |   | Weighted Average Exercise Price |   |   | Weighted Average Remaining Contractual Life (years) |   |   | Aggregate Intrinsic Value (1) |   |
|----------------------------------|--------|------------------|-----------|--------|---------------------------------|--------|--------|-----------------------------------------------------|--------|--------|-------------------------------|--------|
|                             |   |             |      |   |                            |   |   |                                                |   |   | (in thousands)                |   |
| Outstanding at May 31, 2009      |   |             | 2,556,096 |   |                            | $      | 18.26  |                                                |   |   |                          |   |   |   |
| Granted  (2)           |   |             | 342,463   |   |                            | $      | 16.82  |                                                |   |   |                          |   |   |   |
| Exercised  (3)         |   |             | (40,860   | )      |                            | $      | 6.58   |                                                |   |   |                          |   |   |   |
| Forfeited                        |   |             | (95,727   | )      |                            | $      | 25.85  |                                                |   |   |                          |   |   |   |
| Expired                          |   |             | (58,573   | )      |                            | $      | 24.02  |                                                |   |   |                          |   |   |   |
| Outstanding at February 28, 2010 |   |             | 2,703,399 |   |                            | $      | 17.86  |                                                |   |   | 3.9                           |   |   | $ | 14,377 |   |
|                             |   |             |      |   |                            |   |   |                                                |   |   |                          |   |   |   |   |   |
| Exercisable at February 28, 2010 |   |             | 1,654,988 |   |                            | $      | 14.10  |                                                |   |   | 3.5                           |   |   | $ | 13,366 |   |

|   | 1) | The aggregate intrinsic value in the above table represents the total pre-tax intrinsic value (the difference between the Company’s closing stock price on the last trading day of the quarter and the exercise price, multiplied by the number of options that are in the money as of the date presented). |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2) | The weighted-average grant-date fair value of share options granted during the first nine months of fiscal years 2010 and 2009 was $6.50 and $10.54, respectively. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3) | The total intrinsic value of share options exercised during the first nine months of fiscal years 2010 and 2009 was $0.5 million and $13.6 million, respectively. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                             |   | Number of Shares |    |   | Weighted-Average Grant-Date Fair Value |   |
|--------------------------------------------------|--------|------------------|---------|--------|----------------------------------------|--------|
| Nonvested stock outstanding at May 31, 2009      |   |             | 141,190 |   |                                   | $      | 23.72 |   |
| Granted                                          |   |             | 251,512 |   |                                   | $      | 16.27 |   |
| Vested                                           |   |             | (43,416 | )      |                                   | $      | 22.28 |   |
| Forfeited                                        |   |             | (20,948 | )      |                                   | $      | 17.28 |   |
| Nonvested stock outstanding at February 28, 2010 |   |             | 328,338 |   |                                   | $      | 18.62 |   |

----

| 6. | COMPREHENSIVE INCOME |
|----|----------------------|

|                                         |   | Three Months Ended |   |   | Nine Months Ended |   |
|----------------------------------------------|--------|--------------------|--------|--------|-------------------|--------|
|                                         |   | February 28,       |   |   | February 28,      |   |   | February 28, |   |   | February 28, |   |
|                                         |   | 2010               |   |   | 2009              |   |   | 2010 |   |   | 2009 |   |
|                                         |   |               |   |   |              |   |   |   |   |   |   |   |
| Net income                                   |   | $                  | 20,061 |   |              | $      | 19,457 |   |   | $ | 61,096 |   |   | $ | 56,751 |   |
| Net foreign currency translation adjustments |   |               | (5,306 | )      |              |   | (1,084 | ) |   |   | 381 |   |   |   | (12,433 | ) |
| Comprehensive income                         |   | $                  | 14,755 |   |              | $      | 18,373 |   |   | $ | 61,477 |   |   | $ | 44,318 |   |

| 7. | EARNINGS PER SHARE |
|----|--------------------|

|                                                  |   | Three Months Ended |   |         | Nine Months Ended |   |
|-------------------------------------------------------|--------|--------------------|--------|--------------|-------------------|--------|
|                                                  |   | February 28,       |   | February 28, |              |   | February 28, |   |   | February 28, |   |
|                                                  |   | 2010               |   |         | 2009              |   |   | 2010 |   |   | 2009 |   |
|                                                  |   |               |   |         |              |   |   |   |   |   |   |   |
| Numerator for basic and diluted earnings per share:   |   |               |   |         |
| Net Income                                            |   | $                  | 20,061 |         |              | $      | 19,457 |   |   | $ | 61,096 |   |   | $ | 56,751 |   |
| Denominator:                                          |   |               |   |         |              |   |   |   |   |   |   |   |   |   |   |   |
| For basic earnings per share                          |   |               |   |         |              |   |   |   |   |   |   |   |   |   |   |   |
| - weighted average shares basis                       |   |               | 69,869 |         |              |   | 70,406 |   |   |   | 70,121 |   |   |   | 70,361 |   |
| Effect of dilutive stock options and restricted stock |   |               | 587    |         |              |   | 739 |   |   |   | 543 |   |   |   | 834 |   |
| Denominator for diluted earnings per share            |   |               |   |         |              |   |   |   |   |
| -adjusted weighted average shares basis               |   |               | 70,456 |         |              |   | 71,145 |   |   |   | 70,664 |   |   |   | 71,195 |   |
|                                                  |   |               |   |         |              |   |   |   |   |   |   |   |   |   |   |   |
| Earnings per common share – basic               |   | $                  | 0.29   |         |              | $      | 0.28 |   |   | $ | 0.87 |   |   | $ | 0.81 |   |
| Earnings per common share – diluted             |   | $                  | 0.28   |         |              | $      | 0.27 |   |   | $ | 0.86 |   |   | $ | 0.80 |   |

| 8. | SEGMENT AND GEOGRAPHIC INFORMATION |
|----|------------------------------------|

----

|                                            |   | For the Three Months Ended February 28, 2010 |   |
|-------------------------------------------------|--------|----------------------------------------------|--------|
|                                            |   | U.S.                                         |   |   | Europe |   |   | Canada |   |   | Japan |   |   | Elims |   |   | Consolidated |   |
|  Traditional reagent revenues:             |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   | $                                            | 38,660 |   |   | $ | 7,286 |   |   | $ | 2,465 |   |   | $ | 2,099 |   |   | $ | - |   |   | $ | 50,510 |   |
|     Affiliates              |   |                                         | 1,028  |   |   |   | 1,173 |   |   |   | 49 |   |   |   | - |   |   |   | (2,250 | ) |   |   | - |   |
|        Total |   |                                         | 39,688 |   |   |   | 8,459 |   |   |   | 2,514 |   |   |   | 2,099 |   |   |   | (2,250 | ) |   |   | 50,510 |   |
|  Capture revenues:                         |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 10,994 |   |   |   | 5,607 |   |   |   | 1,194 |   |   |   | 285 |   |   |   | - |   |   |   | 18,080 |   |
|     Affiliates              |   |                                         | 1,685  |   |   |   | 708 |   |   |   | - |   |   |   | - |   |   |   | (2,393 | ) |   |   | - |   |
|        Total |   |                                         | 12,679 |   |   |   | 6,315 |   |   |   | 1,194 |   |   |   | 285 |   |   |   | (2,393 | ) |   |   | 18,080 |   |
|  Net instrument revenues:                  |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 6,614  |   |   |   | 3,033 |   |   |   | 562 |   |   |   | 68 |   |   |   | - |   |   |   | 10,277 |   |
|     Affiliates              |   |                                         | 1,150  |   |   |   | 1,052 |   |   |   | - |   |   |   | - |   |   |   | (2,202 | ) |   |   | - |   |
|        Total |   |                                         | 7,764  |   |   |   | 4,085 |   |   |   | 562 |   |   |   | 68 |   |   |   | (2,202 | ) |   |   | 10,277 |   |
|  Net molecular immunohematology revenues:  |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 965    |   |   |   | 667 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 1,632 |   |
|     Affiliates              |   |                                         | 389    |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (389 | ) |   |   | - |   |
|        Total |   |                                         | 1,354  |   |   |   | 667 |   |   |   | - |   |   |   | - |   |   |   | (389 | ) |   |   | 1,632 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net Sales                                 |   |                                         | 61,485 |   |   |   | 19,526 |   |   |   | 4,270 |   |   |   | 2,452 |   |   |   | (7,234 | ) |   |   | 80,499 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Income from operations                    |   |                                         | 24,989 |   |   |   | 3,151 |   |   |   | 2,151 |   |   |   | 296 |   |   |   | 287 |   |   |   | 30,874 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Depreciation                              |   |                                         | 2,089  |   |   |   | 949 |   |   |   | 80 |   |   |   | 26 |   |   |   | - |   |   |   | 3,144 |   |
|  Amortization                              |   |                                         | 1,004  |   |   |   | 40 |   |   |   | - |   |   |   | 21 |   |   |   | - |   |   |   | 1,065 |   |
|  Income tax expense                        |   |                                         | 8,359  |   |   |   | 1,117 |   |   |   | 752 |   |   |   | - |   |   |   | 104 |   |   |   | 10,332 |   |
|  Capital expenditures                      |   |                                         | 1,092  |   |   |   | 38 |   |   |   | 46 |   |   |   | 19 |   |   |   | - |   |   |   | 1,195 |   |

|                                            |   | For the Three Months Ended February 28, 2009 |   |
|-------------------------------------------------|--------|----------------------------------------------|--------|
|                                            |   | U.S.                                         |   |   | Europe |   |   | Canada |   |   | Japan |   |   | Elims |   |   | Consolidated |   |
|  Traditional reagent revenues:             |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   | $                                            | 40,090 |   |   | $ | 6,433 |   |   | $ | 2,011 |   |   | $ | 2,094 |   |   | $ | - |   |   | $ | 50,628 |   |
|     Affiliates              |   |                                         | 1,157  |   |   |   | 1,069 |   |   |   | 45 |   |   |   | - |   |   |   | (2,271 | ) |   |   | - |   |
|        Total |   |                                         | 41,247 |   |   |   | 7,502 |   |   |   | 2,056 |   |   |   | 2,094 |   |   |   | (2,271 | ) |   |   | 50,628 |   |
|  Capture revenues:                         |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 9,531  |   |   |   | 4,947 |   |   |   | 718 |   |   |   | 194 |   |   |   | - |   |   |   | 15,390 |   |
|     Affiliates              |   |                                         | 1,728  |   |   |   | 687 |   |   |   | - |   |   |   | - |   |   |   | (2,415 | ) |   |   | - |   |
|        Total |   |                                         | 11,259 |   |   |   | 5,634 |   |   |   | 718 |   |   |   | 194 |   |   |   | (2,415 | ) |   |   | 15,390 |   |
|  Net instrument revenues:                  |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 5,719  |   |   |   | 1,980 |   |   |   | 407 |   |   |   | 320 |   |   |   | - |   |   |   | 8,426 |   |
|     Affiliates              |   |                                         | 1,608  |   |   |   | 2,373 |   |   |   | - |   |   |   | - |   |   |   | (3,981 | ) |   |   | - |   |
|        Total |   |                                         | 7,327  |   |   |   | 4,353 |   |   |   | 407 |   |   |   | 320 |   |   |   | (3,981 | ) |   |   | 8,426 |   |
| Net molecular immunohematology revenues:        |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                         | 865    |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 865 |   |
|     Affiliates              |   |                                         | 156    |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (156 | ) |   |   | - |   |
|        Total |   |                                         | 1,021  |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (156 | ) |   |   | 865 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net Sales                                 |   |                                         | 60,854 |   |   |   | 17,489 |   |   |   | 3,181 |   |   |   | 2,608 |   |   |   | (8,823 | ) |   |   | 75,309 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Income (loss) from operations             |   |                                         | 27,742 |   |   |   | 782 |   |   |   | 741 |   |   |   | 80 |   |   |   | (47 | ) |   |   | 29,298 |   |
|                                            |   |                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Depreciation                              |   |                                         | 1,283  |   |   |   | 810 |   |   |   | 59 |   |   |   | 46 |   |   |   | - |   |   |   | 2,198 |   |
|  Amortization                              |   |                                         | 989    |   |   |   | 62 |   |   |   | - |   |   |   | 20 |   |   |   | - |   |   |   | 1,071 |   |
|  Income tax (benefit) expense              |   |                                         | 9,294  |   |   |   | 343 |   |   |   | 293 |   |   |   | - |   |   |   | (16 | ) |   |   | 9,914 |   |
|  Capital expenditures                      |   |                                         | 795    |   |   |   | 1,462 |   |   |   | 221 |   |   |   | 8 |   |   |   | - |   |   |   | 2,486 |   |

----

|                                            |   | For the Nine Months Ended February 28, 2010 |    |
|-------------------------------------------------|--------|---------------------------------------------|---------|
|                                            |   | U.S.                                        |    |   | Europe |   |   | Canada |   |   | Japan |   |   | Elims |   |   | Consolidated |   |
|  Traditional reagent revenues:             |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   | $                                           | 120,821 |   |   | $ | 22,237 |   |   | $ | 7,183 |   |   | $ | 6,349 |   |   | $ | - |   |   | $ | 156,590 |   |
|     Affiliates              |   |                                        | 3,450   |   |   |   | 3,665 |   |   |   | 185 |   |   |   | - |   |   |   | (7,300 | ) |   |   | - |   |
|        Total |   |                                        | 124,271 |   |   |   | 25,902 |   |   |   | 7,368 |   |   |   | 6,349 |   |   |   | (7,300 | ) |   |   | 156,590 |   |
|  Capture revenues:                         |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 34,580  |   |   |   | 17,355 |   |   |   | 3,608 |   |   |   | 845 |   |   |   | - |   |   |   | 56,388 |   |
|     Affiliates              |   |                                        | 5,126   |   |   |   | 2,241 |   |   |   | - |   |   |   | - |   |   |   | (7,367 | ) |   |   | - |   |
|        Total |   |                                        | 39,706  |   |   |   | 19,596 |   |   |   | 3,608 |   |   |   | 845 |   |   |   | (7,367 | ) |   |   | 56,388 |   |
|  Net instrument revenues:                  |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 18,666  |   |   |   | 8,773 |   |   |   | 1,699 |   |   |   | 456 |   |   |   | - |   |   |   | 29,594 |   |
|     Affiliates              |   |                                        | 3,783   |   |   |   | 4,297 |   |   |   | - |   |   |   | - |   |   |   | (8,080 | ) |   |   | - |   |
|        Total |   |                                        | 22,449  |   |   |   | 13,070 |   |   |   | 1,699 |   |   |   | 456 |   |   |   | (8,080 | ) |   |   | 29,594 |   |
|  Net molecular immunohematology revenues:  |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 2,376   |   |   |   | 1,193 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 3,569 |   |
|     Affiliates              |   |                                        | 876     |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (876 | ) |   |   | - |   |
|        Total |   |                                        | 3,252   |   |   |   | 1,193 |   |   |   | - |   |   |   | - |   |   |   | (876 | ) |   |   | 3,569 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net Sales                                 |   |                                        | 189,678 |   |   |   | 59,761 |   |   |   | 12,675 |   |   |   | 7,650 |   |   |   | (23,623 | ) |   |   | 246,141 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Income from operations                    |   |                                        | 80,563  |   |   |   | 7,051 |   |   |   | 6,091 |   |   |   | 891 |   |   |   | 283 |   |   |   | 94,879 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Depreciation                              |   |                                        | 5,729   |   |   |   | 2,949 |   |   |   | 249 |   |   |   | 101 |   |   |   | - |   |   |   | 9,028 |   |
|  Amortization                              |   |                                        | 3,019   |   |   |   | 125 |   |   |   | - |   |   |   | 61 |   |   |   | - |   |   |   | 3,205 |   |
|  Income tax expense                        |   |                                        | 28,629  |   |   |   | 2,578 |   |   |   | 2,130 |   |   |   | - |   |   |   | 218 |   |   |   | 33,555 |   |
|  Capital expenditures                      |   |                                        | 5,261   |   |   |   | 280 |   |   |   | 102 |   |   |   | 36 |   |   |   | - |   |   |   | 5,679 |   |
|  Property & equipment, net             |   |                                        | 36,057  |   |   |   | 10,911 |   |   |   | 1,619 |   |   |   | 236 |   |   |   | - |   |   |   | 48,823 |   |
|  Total assets at period end                |   |                                        | 569,537 |   |   |   | 74,524 |   |   |   | 29,779 |   |   |   | 19,642 |   |   |   | (198,599 | ) |   |   | 494,883 |   |

|                                            |   | For the Nine Months Ended February 28, 2009 |    |
|-------------------------------------------------|--------|---------------------------------------------|---------|
|                                            |   | U.S.                                        |    |   | Europe |   |   | Canada |   |   | Japan |   |   | Elims |   |   | Consolidated |   |
|  Traditional reagent revenues:             |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   | $                                           | 115,089 |   |   | $ | 19,248 |   |   | $ | 6,737 |   |   | $ | 6,055 |   |   | $ | - |   |   | $ | 147,129 |   |
|     Affiliates              |   |                                        | 3,852   |   |   |   | 3,183 |   |   |   | 236 |   |   |   | - |   |   |   | (7,271 | ) |   |   | - |   |
|        Total |   |                                        | 118,941 |   |   |   | 22,431 |   |   |   | 6,973 |   |   |   | 6,055 |   |   |   | (7,271 | ) |   |   | 147,129 |   |
|  Capture revenues:                         |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 28,653  |   |   |   | 15,534 |   |   |   | 2,311 |   |   |   | 590 |   |   |   | - |   |   |   | 47,088 |   |
|     Affiliates              |   |                                        | 5,016   |   |   |   | 2,075 |   |   |   | - |   |   |   | - |   |   |   | (7,091 | ) |   |   | - |   |
|        Total |   |                                        | 33,669  |   |   |   | 17,609 |   |   |   | 2,311 |   |   |   | 590 |   |   |   | (7,091 | ) |   |   | 47,088 |   |
|  Net instrument revenues:                  |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 17,063  |   |   |   | 6,896 |   |   |   | 1,189 |   |   |   | 466 |   |   |   | - |   |   |   | 25,614 |   |
|     Affiliates              |   |                                        | 4,051   |   |   |   | 5,468 |   |   |   | - |   |   |   | - |   |   |   | (9,519 | ) |   |   | - |   |
|        Total |   |                                        | 21,114  |   |   |   | 12,364 |   |   |   | 1,189 |   |   |   | 466 |   |   |   | (9,519 | ) |   |   | 25,614 |   |
|  Net molecular immunohematology revenues:  |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Unaffiliated customers  |   |                                        | 1,675   |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 1,675 |   |
|     Affiliates              |   |                                        | 156     |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (156 | ) |   |   | - |   |
|        Total |   |                                        | 1,831   |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (156 | ) |   |   | 1,675 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net Sales                                 |   |                                        | 175,555 |   |   |   | 52,404 |   |   |   | 10,473 |   |   |   | 7,111 |   |   |   | (24,037 | ) |   |   | 221,506 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Income (loss) from operations             |   |                                        | 83,583  |   |   |   | 679 |   |   |   | 3,677 |   |   |   | 128 |   |   |   | (283 | ) |   |   | 87,784 |   |
|                                            |   |                                        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Depreciation                              |   |                                        | 3,969   |   |   |   | 2,642 |   |   |   | 173 |   |   |   | 131 |   |   |   | - |   |   |   | 6,915 |   |
|  Amortization                              |   |                                        | 2,395   |   |   |   | 216 |   |   |   | - |   |   |   | 56 |   |   |   | - |   |   |   | 2,667 |   |
|  Income tax (benefit) expense              |   |                                        | 28,273  |   |   |   | 1,028 |   |   |   | 1,416 |   |   |   | - |   |   |   | (85 | ) |   |   | 30,632 |   |
|  Capital expenditures                      |   |                                        | 2,329   |   |   |   | 3,207 |   |   |   | 526 |   |   |   | 26 |   |   |   | - |   |   |   | 6,088 |   |
|  Property & equipment,  net  |   |                                        | 29,059  |   |   |   | 9,245 |   |   |   | 1,458 |   |   |   | 346 |   |   |   | - |   |   |   | 40,108 |   |
|  Total assets at period end                |   |                                        | 496,065 |   |   |   | 65,772 |   |   |   | 20,774 |   |   |   | 17,516 |   |   |   | (182,584 | ) |   |   | 417,543 |   |

----

|                   |   | Three Months Ended |   |   | Nine Months Ended |   |
|------------------------|--------|--------------------|--------|--------|-------------------|--------|
|                   |   | February 28,       |   |   | February 28,      |   |   | February 28, |   |   | February 28, |   |
|                   |   | 2010               |   |   | 2009              |   |   | 2010 |   |   | 2009 |   |
|                   |   |               |   |   |              |   |   |   |   |   |   |   |
| United States          |   | $                  | 1,373  |   |              | $      | 1,359 |   |   | $ | 4,037 |   |   | $ | 3,613 |   |
| Europe                 |   |               | 1,466  |   |              |   | 971 |   |   |   | 4,831 |   |   |   | 3,760 |   |
| Canada                 |   |               | 387    |   |              |   | 306 |   |   |   | 1,558 |   |   |   | 1,303 |   |
| Total net export sales |   | $                  | 3,226  |   |              | $      | 2,636 |   |   | $ | 10,426 |   |   | $ | 8,676 |   |

| 9. | COMMITMENTS AND CONTINGENCIES |
|----|-------------------------------|

| 10. | RECENT ACCOUNTING PRONOUNCEMENTS |
|-----|----------------------------------|

----

----

|   | 1) A valuation technique that uses |
|--------|------------------------------------|

|   | a. The quoted price of the identical liability when traded as an asset |
|--------|------------------------------------------------------------------------|

|   | b. Quoted prices for similar liabilities or similar liabilities when traded as an asset |
|--------|-----------------------------------------------------------------------------------------|

|   | 2) Another valuation technique that is consistent with the principles of ASC 820, such as an income approach or a market approach. |
|--------|------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

|                                                     |   | Three Months Ended |   |   |         |   |   |   |   |   | Nine Months Ended |   |   |         |   |   |   |   |
|----------------------------------------------------------|--------|--------------------|--------|--------|--------------|--------|--------|--------|--------|--------|-------------------|--------|--------|--------------|--------|--------|--------|--------|
|                                                     |   | February 28,       |   |   | February 28, |   |   | Change |   |   | February 28,      |   |   | February 28, |   |   | Change |   |
|                                                     |   | 2010               |   |   | 2009         |   |   | Amount |   |   | %                 |   |   | 2010         |   |   | 2009   |   |   | Amount |   |   | % |   |
|                                                     |   | ($ in thousands)   |   |   |         |   |   |   |   |   | ($ in thousands)  |   |   |         |   |   |   |   |
| Net sales                                                |   | $                  | 80,499 |   |         | $      | 75,309 |   |   | $      | 5,190             |   |   |         | 7      | %      |   | $      | 246,141 |   |   | $ | 221,506 |   |   | $ | 24,635 |   |   |   | 11 | % |
| Gross margin                                             |   |               | 55,714 |   |         |   | 53,789 |   |   |   | 1,925             |   |   |         | 4      | %      |   |   | 173,543 |   |   |   | 160,772 |   |   |   | 12,771 |   |   |   | 8 | % |
| Gross margin percentage                                  |   |               | 69.2   | %      |         |   | 71.4   | %      |   |   |              |   |   |         |   |   |   |   | 70.5 | % |   |   | 72.6 | % |   |   |   |   |   |   |   |   |
| Operating expenses                                       |   |               | 24,840 |   |         |   | 24,491 |   |   |   | 349               |   |   |         | 1      | %      |   |   | 78,664 |   |   |   | 72,988 |   |   |   | 5,676 |   |   |   | 8 | % |
| Income from operations                                   |   |               | 30,874 |   |         |   | 29,298 |   |   |   | 1,576             |   |   |         | 5      | %      |   |   | 94,879 |   |   |   | 87,784 |   |   |   | 7,095 |   |   |   | 8 | % |
| Non-operating income                                     |   |               | (481   | )      |         |   | 73     |   |   |   | (554              | )      |   |         | -759   | %      |   |   | (228 | ) |   |   | (401 | ) |   |   | 173 |   |   |   | -43 | % |
| Income before income tax                                 |   |               | 30,393 |   |         |   | 29,371 |   |   |   | 1,022             |   |   |         | 3      | %      |   |   | 94,651 |   |   |   | 87,383 |   |   |   | 7,268 |   |   |   | 8 | % |
| Provision for income tax                                 |   |               | 10,332 |   |         |   | 9,914  |   |   |   | 418               |   |   |         | 4      | %      |   |   | 33,555 |   |   |   | 30,632 |   |   |   | 2,923 |   |   |   | 10 | % |
| Net income                                               |   | $                  | 20,061 |   |         | $      | 19,457 |   |   | $      | 604               |   |   |         | 3      | %      |   | $      | 61,096 |   |   | $ | 56,751 |   |   | $ | 4,345 |   |   |   | 8 | % |
|                                                     |   |               |   |   |         |   |   |   |   |   |              |   |   |         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Earnings per share:                                      |   |               |   |   |         |   |   |   |   |   |              |   |   |         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|      Per common share - basic   |   | $                  | 0.29   |   |         | $      | 0.28   |   |   | $      | 0.01              |   |   |         | 4      | %      |   | $      | 0.87 |   |   | $ | 0.81 |   |   | $ | 0.06 |   |   |   | 7 | % |
|      Per common share - diluted |   | $                  | 0.28   |   |         | $      | 0.27   |   |   | $      | 0.01              |   |   |         | 4      | %      |   | $      | 0.86 |   |   | $ | 0.80 |   |   | $ | 0.06 |   |   |   | 7 | % |

----

|                       |   | Three Months Ended |   |   |         |   |   |   |   |   | Nine Months Ended |   |   |         |   |   |   |   |
|----------------------------|--------|--------------------|--------|--------|--------------|--------|--------|--------|--------|--------|-------------------|--------|--------|--------------|--------|--------|--------|--------|
|                       |   | February 28,       |   |   | February 28, |   |   | Change |   |   | February 28,      |   |   | February 28, |   |   | Change |   |
|                       |   | 2010               |   |   | 2009         |   |   | Amount |   |   | %                 |   |   | 2010         |   |   | 2009   |   |   | Amount |   |   | % |   |
|                       |   | ($ in thousands)   |   |   |         |   |   |   |   |   | ($ in thousands)  |   |   |         |   |   |   |   |
| Traditional reagents       |   | $                  | 50,510 |   |         | $      | 50,628 |   |   | $      | (118              | )      |   |         | 0      | %      |   | $      | 156,590 |   |   | $ | 147,129 |   |   | $ | 9,461 |   |   |   | 6 | % |
| Capture products           |   |               | 18,080 |   |         |   | 15,390 |   |   |   | 2,690             |   |   |         | 17     | %      |   |   | 56,388 |   |   |   | 47,088 |   |   |   | 9,300 |   |   |   | 20 | % |
| Instruments                |   |               | 10,277 |   |         |   | 8,426  |   |   |   | 1,851             |   |   |         | 22     | %      |   |   | 29,594 |   |   |   | 25,614 |   |   |   | 3,980 |   |   |   | 16 | % |
| Molecular immunohematology |   |               | 1,632  |   |         |   | 865    |   |   |   | 767               |   |   |         | 89     | %      |   |   | 3,569 |   |   |   | 1,675 |   |   |   | 1,894 |   |   |   | 113 | % |
|                       |   | $                  | 80,499 |   |         | $      | 75,309 |   |   | $      | 5,190             |   |   |         | 7      | %      |   | $      | 246,141 |   |   | $ | 221,506 |   |   | $ | 24,635 |   |   |   | 11 | % |

----

|                           |   | Three Months Ended |   |   |         |   |
|--------------------------------|--------|--------------------|--------|--------|--------------|--------|
|                           |   | February 28,       |   |   | February 28, |   |   |   |   |
|                           |   | 2010               |   |   | 2009         |   |   | Change |   |
|                           |   | Amount             |   |   | Margin %     |   | Amount |   |   | Margin % |   | Amount |   |
|                           |   | (in '000)          |   |   |         |   |   | (in '000) |   |   |   |   |   | (in '000) |   |
| Traditional reagents (1)       |   | $                  | 39,084 |   |         |   | 77.4 | % |   | $ | 39,530 |   |   |   | 78.1 | % |   | $ | (446 | ) |
| Capture products (1)           |   |               | 14,496 |   |         |   | 80.2 | % |   |   | 12,927 |   |   |   | 84.0 | % |   |   | 1,569 |   |
| Instruments (1)                |   |               | 1,614  |   |         |   | 15.7 | % |   |   | 1,024 |   |   |   | 12.2 | % |   |   | 590 |   |
| Molecular immunohematology (1) |   |               | 520    |   |         |   | 31.9 | % |   |   | 308 |   |   |   | 35.6 | % |   |   | 212 |   |
|                           |   | $                  | 55,714 |   |         |   | 69.2 | % |   | $ | 53,789 |   |   |   | 71.4 | % |   | $ | 1,925 |   |

|                           |   | Nine Months Ended |    |   |         |   |
|--------------------------------|--------|-------------------|---------|--------|--------------|--------|
|                           |   | February 28,      |    |   | February 28, |   |   |   |   |
|                           |   | 2010              |    |   | 2009         |   |   | Change |   |
|                           |   | Amount            |    |   | Margin %     |   | Amount |   |   | Margin % |   | Amount |   |
|                           |   | (in '000)         |    |   |         |   |   | (in '000) |   |   |   |   |   | (in '000) |   |
| Traditional reagents (1)       |   | $                 | 120,165 |   |         |   | 76.7 | % |   | $ | 116,469 |   |   |   | 79.2 | % |   | $ | 3,696 |   |
| Capture products (1)           |   |              | 46,061  |   |         |   | 81.7 | % |   |   | 40,071 |   |   |   | 85.1 | % |   |   | 5,990 |   |
| Instruments (1)                |   |              | 6,794   |   |         |   | 23.0 | % |   |   | 3,631 |   |   |   | 14.2 | % |   |   | 3,163 |   |
| Molecular immunohematology (1) |   |              | 523     |   |         |   | 14.7 | % |   |   | 601 |   |   |   | 35.9 | % |   |   | (78 | ) |
|                           |   | $                 | 173,543 |   |         |   | 70.5 | % |   | $ | 160,772 |   |   |   | 72.6 | % |   | $ | 12,771 |   |

| (1)  The determination of gross margin is exclusive of amortization expense which is presented separately as an operating expense in the income statement. |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                                                             |   | Three Months Ended |   |   |         |   |   |   |   |   | Nine Months Ended |   |   |         |   |   |     |   |
|------------------------------------------------------------------------------------------------------------------|--------|--------------------|--------|--------|--------------|--------|--------|--------|--------|--------|-------------------|--------|--------|--------------|--------|--------|----------|--------|
|                                                                                                             |   | February 28,       |   |   | February 28, |   |   | Change |   |   | February 28,      |   |   | February 28, |   |   | Change   |   |
|                                                                                                             |   | 2010               |   |   | 2009 (1)     |   |   | Amount |   |   | %                 |   |   | 2010         |   |   | 2009 (1) |   |   | Amount |   |   | % |   |
|                                                                                                             |   | ($ in thousands)   |   |   |         |   |   |   |   |   | ($ in thousands)  |   |   |         |   |   |     |   |
| Research and development                                                                                         |   | $                  | 3,409  |   |         | $      | 2,777  |   |   | $      | 632               |   |   |         | 23     | %      |     | $      | 11,130 |   |   | $ | 7,553 |   |   | $ | 3,577 |   |   |   | 47 | % |
| Selling and marketing                                                                                            |   |               | 8,388  |   |         |   | 8,894  |   |   |   | (506              | )      |   |         | -6     | %      |     |   | 27,617 |   |   |   | 28,626 |   |   |   | (1,009 | ) |   |   | -4 | % |
| Distribution                                                                                                     |   |               | 3,579  |   |         |   | 3,309  |   |   |   | 270               |   |   |         | 8      | %      |     |   | 10,805 |   |   |   | 10,326 |   |   |   | 479 |   |   |   | 5 | % |
| General and administrative                                                                                       |   |               | 8,399  |   |         |   | 8,440  |   |   |   | (41               | )      |   |         | 0      | %      |     |   | 25,907 |   |   |   | 23,816 |   |   |   | 2,091 |   |   |   | 9 | % |
| Amortization expense                                                                                             |   |               | 1,065  |   |         |   | 1,071  |   |   |   | (6                | )      |   |         | -1     | %      |     |   | 3,205 |   |   |   | 2,667 |   |   |   | 538 |   |   |   | 20 | % |
| Total operating expenses                                                                                         |   | $                  | 24,840 |   |         | $      | 24,491 |   |   | $      | 349               |   |   |         | 1      | %      |     | $      | 78,664 |   |   | $ | 72,988 |   |   | $ | 5,676 |   |   |   | 8 | % |
|                                                                                                             |   |               |   |   |         |   |   |   |   |   |              |   |   |         |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (1) Certain prior year operating expenses have been reclassified to conform with current year presentation. |   |               |   |   |         |   |   |   |   |

|                           |   | Three Months Ended |   |   |         |   |   | Nine Months Ended |   |   |         |   |
|--------------------------------|--------|--------------------|--------|--------|--------------|--------|--------|-------------------|--------|--------|--------------|--------|
|                           |   | February 28,       |   |   | February 28, |   |   | Change            |   |   | February 28, |   |   | February 28, |   |   | Change |   |
|                           |   | 2010               |   |   | 2009         |   |   | Amount            |   |   | 2010         |   |   | 2009 |   |   | Amount |   |
|                           |   | ($ in thousands)   |   |   |         |   |   | ($ in thousands)  |   |   |         |   |
| Non-operating income (expense) |   | $                  | (481   | )      |         | $      | 73     |              |   | $      | (554         | )      |   | $ | (228 | ) |   | $ | (401 | ) |   | $ | 173 |   |

----

|                                                                                       |   | For the Nine Months Ended |    |
|--------------------------------------------------------------------------------------------|--------|---------------------------|---------|
|                                                                                       |   | February 28, 2010         |    |   | February 28, 2009 |   |
|                                                                                       |   | (in thousands)            |    |
| Net cash provided by operating activities                                                  |   | $                         | 55,523  |   |   | $ | 54,033 |   |
| Net cash used in investing activities                                                      |   |                      | (5,679  | ) |   |   | (114,747 | ) |
| Net cash provided by (used in) financing activities                                        |   |                      | (11,249 | ) |   |   | 1,597 |   |
| Effect of exchange rate changes on cash and cash equivalents                               |   |                      | 566     |   |   |   | (2,514 | ) |
|        Increase (decrease) in cash and cash equivalents |   | $                         | 39,161  |   |   | $ | (61,631 | ) |

----

|   | i.  | Revenue recognition |
|--------|----------|---------------------|

|   | ii.  | Trade accounts receivable and allowance for doubtful accounts |
|--------|-----------|---------------------------------------------------------------|

|   | iii.  | Inventories |
|--------|------------|-------------|

|   | iv.  | Goodwill |
|--------|-----------|----------|

|   | v.  | Income taxes |
|--------|----------|--------------|

|   | vi.  | Share-based compensation |
|--------|-----------|--------------------------|

----

|   | ● | Reagent sales |
|--------|---------|---------------|

|   | ● | Medical instrument sales |
|--------|---------|--------------------------|

----

----

|   | ● | there have been no material developments concerning the investigations of the Company by the United States Department of Justice or the Federal Trade Commission. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | the United States District Court for the Eastern District of Pennsylvania consolidated for pretrial purposes the lawsuits against the Company, Ortho-Clinical Diagnostics, Inc. and Johnson & Johnson Health Care Systems, Inc., which asserted claims under Section 1 of the Sherman Act. These cases are identified in Exhibit 99.1, which is hereby incorporated herein by reference.  There have been no other material developments in these cases. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | the class action lawsuit filed in August 2009 in the United States District Court for the Eastern District of Pennsylvania against the Company and ten of its current and former directors and officers alleging certain violations of the Securities Exchange Act of 1934 (Schlenker v. Immucor, Inc., et al., Civil Action No. 2:09-CV-04297-JD (E.D. Pa.)) was transferred to the United States District Court for the Northern District of Georgia and subsequently dismissed without prejudice.  That court has appointed the Colleges of Applied Arts and Technology Pension Plan as lead plaintiff for the remaining action (City of Pontiac General Employees’ Retirement System v. Immucor, Inc., et al., Civil Action No. 1:09-CV-2351-TWT (N.D. Ga.)), which is now styled In re Immucor, Inc. Securities Litigation.  There have been no other material developments in these cases. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 31.1  | Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a). |
|--------|------------|---------------------------------------------------------------------------------------------|

|   | 31.2  | Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a). |
|--------|------------|---------------------------------------------------------------------------------------------|

|   | 32.1  | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|--------|------------|-----------------------------------------------------------------------------------------------------|

|   | 32.2  | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|--------|------------|-----------------------------------------------------------------------------------------------------|

|   | 99.1  | Summary of Lawsuits (incorporated by reference to Exhibit 99.1 to Immucor, Inc.’s quarterly report on Form 10-Q filed on October 2, 2009). |
|--------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                           | IMMUCOR, INC.(Registrant) |                                                                                                           |
|--------------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------|
|                           |                      |                                                                                                           |   |
|                           |                      |                                                                                                           |   |
| Date:  April 1, 2010 | By:                       | /s/ Dr. Gioacchino De Chirico                                                                             |   |
|                           |                      | Dr. Gioacchino De Chirico, Chief Executive Officer(on behalf of Registrant and as Principal Executive Officer) |   |
|                           |                      |                                                                                                           |   |
|                           |                      |                                                                                                           |   |
| Date:  April 1, 2010 | By:                       | /s/ Richard A. Flynt                                                                                           |   |
|                           |                      | Richard A. Flynt, Chief Financial Officer(Principal Financial and Accounting Officer)                          |   |

----

| Number  | Description |
|--------------|-------------|

| 31.1  | Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a). |
|------------|---------------------------------------------------------------------------------------------|

| 31.2  | Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a). |
|------------|---------------------------------------------------------------------------------------------|

| 32.1  | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|------------|-----------------------------------------------------------------------------------------------------|

| 32.2  | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|------------|-----------------------------------------------------------------------------------------------------|